Metabolic syndrome and cardiovascular risk in primary hypertension
Elena Ratto1, Giovanna Leoncini, Francesca Viazzi
1Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
Insights
Metabolic syndrome is common in primary hypertension patients without diabetes, increasing cardiovascular and renal risks. Drug choice is crucial, favoring renin-angiotensin system inhibitors and calcium channel blockers.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Metabolic syndrome affects one-third of patients with primary hypertension but no diabetes.
- It is linked to numerous cardiovascular risk factors and early cardiovascular/renal damage.
- Metabolic syndrome is a predictor of increased cardiovascular events and mortality.
Purpose of the Study:
- To highlight the significance of metabolic syndrome in hypertensive patients.
- To emphasize the impact of antihypertensive drugs on metabolic syndrome.
- To guide drug selection in patients with insulin resistance.
Main Methods:
- Review of existing literature on metabolic syndrome and hypertension.
- Analysis of cardiovascular risk factors associated with metabolic syndrome.
- Evaluation of metabolic side effects of different antihypertensive drug classes.
Main Results:
- Metabolic syndrome is prevalent in hypertensive individuals without diabetes.
- Association with diverse cardiovascular and renal risk factors is confirmed.
- Metabolic syndrome independently predicts adverse cardiovascular outcomes.
Conclusions:
- Hypertensive patients with metabolic syndrome face elevated cardiovascular and renal risks.
- Antihypertensive medication choice impacts metabolic profiles.
- Renin-angiotensin system inhibitors and calcium channel blockers are preferred over beta blockers and diuretics in this population.
Abstract:
The metabolic syndrome can be found in approximately one third of patients who do not have diabetes but have primary hypertension. Its presence has been associated with a wide range of traditional and nontraditional cardiovascular risk factors and early signs of cardiovascular and renal damage. Moreover, it was emphasized recently that the metabolic syndrome predicts an increased probability of sustaining a cardiovascular event or dying. In the clinical setting of insulin resistance, attention should be paid to the metabolic side effects of antihypertensive drugs; therefore, preference should be given to renin-angiotensin system inhibitors and calcium channel blockers rather than to beta blockers and diuretics.
More Related Videos
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Related Concept Videos
Coronary Artery Disease I: Introduction
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Cholesterol: Significance and Regulation
Considering cholesterol and...
